1
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Conditions
Urinary Bladder Neoplasms
2
Hormone Refractory Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
3202
Cyclophosphamide
3195
Carboplatin
2977
Radiotherapy
2790
Paclitaxel
2718
Gemcitabine
2572
pembrolizumab
2385
Bevacizumab
2209
Docetaxel
2199
Fluorouracil
1851
Capecitabine
1833
Oxaliplatin
1742
Dexamethasone
1605
Nivolumab
1581
Doxorubicin
1501
Rituximab
1488
Magnetic Resonance Spectroscopy
1387
Etoposide
1346
Irinotecan
1248
Leucovorin
1226
Drug Therapy
1205
Cytarabine
1130
Pemetrexed
1076
fludarabine
1063
Specimen Handling
1017
Vincristine
964
Cetuximab
945
Trastuzumab
945
Prednisone
942
Lenalidomide
937
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Mycobacterium w vaccine
×
Clear all
NCT00694915
2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2
Completed
122 enrolled
NCT00680940
2012-08-07
NSCLC
Cadila Pharnmaceuticals
Phase 2
Completed
221 enrolled
NCT00694798
2012-05-03
STCC
Cadila Pharnmaceuticals
Phase 1
Completed
22 enrolled
NCT00525408
2012-03-12
HRPC
Cadila Pharnmaceuticals
Phase 2
Terminated
134 enrolled